Activotec announces further business expansion
Advertisement
Activotec has announced a major expansion of its Cambridge, UK Headquarters and investment in new sales and production staff to meet the demand for its Activo-P11 Peptide Synthesize.
Chris Littlewood, Chief Executive of Activotec, commented "2008 peptide synthesizer sales have exceeded even our most optimistic expectations". He added "We are the only European company with international service and support teams that are exclusively focused on peptide synthesis instrumentation and services. This enables Activotec to be uniquely positioned to provide customers with informed technical assistance enabling them to get the most from their peptide synthesizer".
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
BioVaria Startup Awards go to OPSYON and LIfT Biosciences - 11th BioVaria Sees Record Attendance
Phylogica licenses technology to Janssen Biotech, Inc.
Biotools, B & M Labs, S.A. - Madrid, Spain
Structure of key complex in the immune system - New study reveals the structure of complement component C1 – a target for complement-mediated diseases including strokes and heart attacks
Computer tool analyzes in detail genetic alterations in the genome of cancer cells - Developed by CSIC, CiberAMP allows establishing direct correlations between changes in the number of gene copies in tumor cells and their expression levels
Proteros and CHDI Foundation, Inc. establish discovery services collaboration to address Huntington’s disease
Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform